Logo image of SERA

SERA PROGNOSTICS INC-A (SERA) Stock Fundamental Analysis

USA - NASDAQ:SERA - US81749D1072 - Common Stock

3.25 USD
+0.12 (+3.83%)
Last: 10/3/2025, 8:03:14 PM
Fundamental Rating

3

Taking everything into account, SERA scores 3 out of 10 in our fundamental rating. SERA was compared to 536 industry peers in the Biotechnology industry. The financial health of SERA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SERA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SERA had negative earnings in the past year.
In the past year SERA has reported a negative cash flow from operations.
SERA had negative earnings in each of the past 5 years.
SERA had a negative operating cash flow in each of the past 5 years.
SERA Yearly Net Income VS EBIT VS OCF VS FCFSERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

SERA has a better Return On Assets (-29.27%) than 67.35% of its industry peers.
With a decent Return On Equity value of -37.10%, SERA is doing good in the industry, outperforming 74.07% of the companies in the same industry.
Industry RankSector Rank
ROA -29.27%
ROE -37.1%
ROIC N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
SERA Yearly ROA, ROE, ROICSERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

SERA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SERA Yearly Profit, Operating, Gross MarginsSERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SERA has more shares outstanding
SERA has more shares outstanding than it did 5 years ago.
SERA has a better debt/assets ratio than last year.
SERA Yearly Shares OutstandingSERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SERA Yearly Total Debt VS Total AssetsSERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

SERA has an Altman-Z score of -1.58. This is a bad value and indicates that SERA is not financially healthy and even has some risk of bankruptcy.
SERA has a Altman-Z score (-1.58) which is in line with its industry peers.
SERA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.58
ROIC/WACCN/A
WACC10.01%
SERA Yearly LT Debt VS Equity VS FCFSERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.73 indicates that SERA should not have too much problems paying its short term obligations.
SERA's Current ratio of 1.73 is on the low side compared to the rest of the industry. SERA is outperformed by 78.92% of its industry peers.
A Quick Ratio of 1.73 indicates that SERA should not have too much problems paying its short term obligations.
SERA's Quick ratio of 1.73 is on the low side compared to the rest of the industry. SERA is outperformed by 77.99% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
SERA Yearly Current Assets VS Current LiabilitesSERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

SERA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.27%, which is quite good.
SERA shows a small growth in Revenue. In the last year, the Revenue has grown by 2.86%.
The Revenue has been growing by 14.00% on average over the past years. This is quite good.
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-29.17%

3.2 Future

SERA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.82% yearly.
Based on estimates for the next years, SERA will show a very strong growth in Revenue. The Revenue will grow by 195.78% on average per year.
EPS Next Y21.7%
EPS Next 2Y7.96%
EPS Next 3Y14.08%
EPS Next 5Y8.82%
Revenue Next Year118.18%
Revenue Next 2Y255.5%
Revenue Next 3Y236.73%
Revenue Next 5Y195.78%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SERA Yearly Revenue VS EstimatesSERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
SERA Yearly EPS VS EstimatesSERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SERA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SERA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SERA Price Earnings VS Forward Price EarningsSERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SERA Per share dataSERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as SERA's earnings are expected to grow with 14.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.96%
EPS Next 3Y14.08%

More info and screens

0

5. Dividend

5.1 Amount

SERA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERA PROGNOSTICS INC-A

NASDAQ:SERA (10/3/2025, 8:03:14 PM)

3.25

+0.12 (+3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners64.87%
Inst Owner Change-7.76%
Ins Owners2.66%
Ins Owner Change-0.14%
Market Cap123.69M
Analysts85
Price TargetN/A
Short Float %1.93%
Short Ratio6.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.52%
Min EPS beat(2)14.75%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)8.99%
Min EPS beat(4)-6.95%
Max EPS beat(4)30.28%
EPS beat(8)6
Avg EPS beat(8)11.42%
EPS beat(12)10
Avg EPS beat(12)13.93%
EPS beat(16)11
Avg EPS beat(16)5.03%
Revenue beat(2)0
Avg Revenue beat(2)-63.9%
Min Revenue beat(2)-74.36%
Max Revenue beat(2)-53.43%
Revenue beat(4)1
Avg Revenue beat(4)-34.37%
Min Revenue beat(4)-74.36%
Max Revenue beat(4)56.86%
Revenue beat(8)1
Avg Revenue beat(8)-48.2%
Revenue beat(12)3
Avg Revenue beat(12)-35.67%
Revenue beat(16)3
Avg Revenue beat(16)-38.4%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.89%
EPS NY rev (1m)0%
EPS NY rev (3m)14.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-13.04%
Revenue NY rev (1m)-11.11%
Revenue NY rev (3m)-35.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1145.32
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS2.32
TBVpS2.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.27%
ROE -37.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.79%
Cap/Sales 615.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -1.58
F-Score3
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)83.45%
Cap/Depr(5y)92.8%
Cap/Sales(3y)588.1%
Cap/Sales(5y)777.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y21.7%
EPS Next 2Y7.96%
EPS Next 3Y14.08%
EPS Next 5Y8.82%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-29.17%
Revenue Next Year118.18%
Revenue Next 2Y255.5%
Revenue Next 3Y236.73%
Revenue Next 5Y195.78%
EBIT growth 1Y-4.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.86%
OCF growth 3YN/A
OCF growth 5YN/A